We’re delighted to announce OncoOne’s latest publication in MDPI Antibodies!

In our latest publication, we explore how combining in silico tools with experimental validation can enhance antibody engineering. Focusing on the first-generation anti-oxMIF antibody, imalumab, we uncovered surface hydrophobicity and aggregation as key factors limiting its effectiveness. Through targeted mutations, we transformed these challenges into opportunities, developing C0083—a lead candidate with improved biophysicochemical properties, reduced immunogenicity risk, and enhanced pharmacokinetics. 

Structural analysis revealed that restructuring the CDR3 loop of the heavy chain plays a key role in maintaining high specificity and affinity for oxMIF. This study demonstrates how molecular bioengineering can unlock the potential of antibodies, paving the way for promising anti-oxMIF therapies for cancer and inflammatory diseases.

You can read more about our findings at https://doi.org/10.3390/antib13040104

Congratulations to first author Gregor Rossmüller for his outstanding contributions and many thanks to MDPI for the smooth editorial process! We are proud of the dedication of our team and would like to extend a special thank you to all individuals who contributed to this achievement.